MX392259B - ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a - Google Patents
ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5aInfo
- Publication number
- MX392259B MX392259B MX2019014294A MX2019014294A MX392259B MX 392259 B MX392259 B MX 392259B MX 2019014294 A MX2019014294 A MX 2019014294A MX 2019014294 A MX2019014294 A MX 2019014294A MX 392259 B MX392259 B MX 392259B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- fused
- rings
- modulators
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Liquid Crystal Substances (AREA)
- Glass Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513010P | 2017-05-31 | 2017-05-31 | |
| PCT/US2018/034905 WO2018222598A1 (en) | 2017-05-31 | 2018-05-29 | 6-5 FUSED RINGS AS C5a INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX392259B true MX392259B (es) | 2025-03-24 |
Family
ID=64456009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014294A MX392259B (es) | 2017-05-31 | 2018-05-29 | ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10562896B2 (enExample) |
| EP (1) | EP3630775B1 (enExample) |
| JP (1) | JP7141130B2 (enExample) |
| KR (1) | KR102638253B1 (enExample) |
| CN (1) | CN110997674B (enExample) |
| AR (1) | AR111983A1 (enExample) |
| AU (1) | AU2018277520B2 (enExample) |
| IL (1) | IL270828B2 (enExample) |
| MA (1) | MA48803A (enExample) |
| MX (1) | MX392259B (enExample) |
| NZ (1) | NZ759297A (enExample) |
| TW (1) | TWI781177B (enExample) |
| WO (1) | WO2018222598A1 (enExample) |
| ZA (1) | ZA201907746B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7141129B2 (ja) | 2017-05-31 | 2022-09-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａ阻害剤としての５－５融合環 |
| KR102638253B1 (ko) * | 2017-05-31 | 2024-02-16 | 케모센트릭스, 인크. | C5a 억제제로서의 6-5 융합 고리 |
| MA51327A (fr) | 2017-12-22 | 2021-05-26 | Chemocentryx Inc | Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar |
| MX2020006459A (es) | 2017-12-22 | 2020-11-06 | Chemocentryx Inc | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. |
| ES2993034T3 (en) * | 2018-04-02 | 2024-12-20 | Chemocentryx Inc | Prodrugs of fused-bicyclic c5ar antagonists |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| CN112625036A (zh) | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| ES3068390T3 (en) | 2019-10-16 | 2026-05-29 | Chemocentryx Inc | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| AU2020368392B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| EP4178955A1 (en) | 2020-07-11 | 2023-05-17 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US20220047592A1 (en) * | 2020-08-13 | 2022-02-17 | Chemocentryx, Inc. | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CA3192880A1 (en) | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK27383A (da) | 1982-02-17 | 1983-08-18 | Lepetit Spa | Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner |
| GB8613591D0 (en) | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| CA2416527C (en) | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| AU7622500A (en) | 2000-09-29 | 2002-07-01 | Neurogen Corp | High affinity small molecule c5a receptor modulators |
| SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
| US7902179B2 (en) | 2001-04-26 | 2011-03-08 | Ajinomoto Co., Inc. | Heterocyclic compounds |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| WO2003082828A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| CA2479928A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted biaryl amides as c5a receptor modulators |
| WO2003084524A1 (en) | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| WO2004016592A1 (en) * | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| EP1928461B1 (en) | 2005-08-04 | 2012-01-04 | Janssen Pharmaceutica NV | Pyrimidine compounds as serotonin receptor modulators |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| US20080119457A1 (en) | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
| PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| IN2012DN00721A (enExample) | 2009-09-02 | 2015-06-19 | Merck Sharp & Dohme | |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| US8846656B2 (en) * | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| PE20151139A1 (es) | 2012-08-16 | 2015-08-07 | Janssen Pharmaceutica Nv | Pirrolopirazoles como bloqueadores del canal de calcio tipo n |
| CN103421006B (zh) * | 2013-08-18 | 2016-06-22 | 上海师范大学 | 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用 |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SG11201808625QA (en) | 2016-04-04 | 2018-10-30 | Chemocentryx Inc | SOLUBLE C5aR ANTAGONISTS |
| KR102638253B1 (ko) | 2017-05-31 | 2024-02-16 | 케모센트릭스, 인크. | C5a 억제제로서의 6-5 융합 고리 |
| JP7141129B2 (ja) | 2017-05-31 | 2022-09-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａ阻害剤としての５－５融合環 |
| US10589871B2 (en) | 2017-09-25 | 2020-03-17 | Hamilton Sundstrand Corporation | Prognostic health monitoring and jam detection for use with an aircraft |
| MX2020006459A (es) | 2017-12-22 | 2020-11-06 | Chemocentryx Inc | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. |
| MA51327A (fr) | 2017-12-22 | 2021-05-26 | Chemocentryx Inc | Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar |
| ES2993034T3 (en) | 2018-04-02 | 2024-12-20 | Chemocentryx Inc | Prodrugs of fused-bicyclic c5ar antagonists |
-
2018
- 2018-05-29 KR KR1020197038669A patent/KR102638253B1/ko active Active
- 2018-05-29 NZ NZ759297A patent/NZ759297A/en unknown
- 2018-05-29 CN CN201880036662.0A patent/CN110997674B/zh active Active
- 2018-05-29 WO PCT/US2018/034905 patent/WO2018222598A1/en not_active Ceased
- 2018-05-29 US US15/991,703 patent/US10562896B2/en active Active
- 2018-05-29 AU AU2018277520A patent/AU2018277520B2/en active Active
- 2018-05-29 EP EP18809537.6A patent/EP3630775B1/en active Active
- 2018-05-29 MA MA048803A patent/MA48803A/fr unknown
- 2018-05-29 JP JP2019565833A patent/JP7141130B2/ja active Active
- 2018-05-29 MX MX2019014294A patent/MX392259B/es unknown
- 2018-05-31 TW TW107118601A patent/TWI781177B/zh active
- 2018-05-31 AR ARP180101449A patent/AR111983A1/es active IP Right Grant
-
2019
- 2019-11-21 IL IL270828A patent/IL270828B2/en unknown
- 2019-11-22 ZA ZA2019/07746A patent/ZA201907746B/en unknown
- 2019-12-20 US US16/723,433 patent/US11384079B2/en active Active
-
2022
- 2022-05-03 US US17/735,283 patent/US11773091B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI781177B (zh) | 2022-10-21 |
| TW201902895A (zh) | 2019-01-16 |
| JP7141130B2 (ja) | 2022-09-22 |
| EP3630775A4 (en) | 2020-10-07 |
| MA48803A (fr) | 2020-04-08 |
| WO2018222598A1 (en) | 2018-12-06 |
| KR20200015604A (ko) | 2020-02-12 |
| CA3064017A1 (en) | 2018-12-06 |
| CN110997674B (zh) | 2022-12-20 |
| RU2019142942A3 (enExample) | 2021-09-03 |
| AU2018277520B2 (en) | 2022-03-17 |
| US10562896B2 (en) | 2020-02-18 |
| US11773091B2 (en) | 2023-10-03 |
| EP3630775B1 (en) | 2022-12-14 |
| NZ759297A (en) | 2026-03-27 |
| US20230151002A1 (en) | 2023-05-18 |
| IL270828B2 (en) | 2023-04-01 |
| AR111983A1 (es) | 2019-09-11 |
| CN110997674A (zh) | 2020-04-10 |
| US20180370967A1 (en) | 2018-12-27 |
| IL270828A (en) | 2020-01-30 |
| KR102638253B1 (ko) | 2024-02-16 |
| BR112019025049A2 (pt) | 2020-06-16 |
| IL270828B (en) | 2022-12-01 |
| ZA201907746B (en) | 2023-10-25 |
| US11384079B2 (en) | 2022-07-12 |
| EP3630775A1 (en) | 2020-04-08 |
| AU2018277520A1 (en) | 2019-12-12 |
| JP2020522484A (ja) | 2020-07-30 |
| RU2019142942A (ru) | 2021-06-30 |
| US20200347049A1 (en) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907746B (en) | 6-5 fused rings as c5a inhibitors | |
| MX391392B (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a. | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| MX2020006460A (es) | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| MX383124B (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus. | |
| MX391221B (es) | Compuestos y composiciones y usos de los mismos. | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| PH12018500432A1 (en) | Heteroaryl compounds and their use as therapeutic drugs | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| EA202090414A1 (ru) | Соединения и их применение | |
| MX381129B (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| JOP20190183B1 (ar) | معدِلات مستقبلات الاستروجين | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EA201691796A1 (ru) | П-замещенные асимметричные мочевины и их применение в медицине | |
| EA201990399A1 (ru) | Соединения, композиции и их применение | |
| EA201892529A1 (ru) | Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы | |
| MX369806B (es) | Compuestos de indolona y su uso como moduladores del receptor ampa. | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
| JOP20200104B1 (ar) | مركبات مثبطة لـ btk | |
| EA201992051A1 (ru) | Агонисты фарнезоидного x-рецептора и их применение |